Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]
Follow Us
-
+1 700 888 1234
-
Effingerstrasse 40 3008 Bern Switzerland
+1 700 888 1234
Effingerstrasse 40 3008 Bern Switzerland
Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]
We’re delighted to welcome five new member organisations to our growing Lung Cancer Europe (LuCE) network. These organisations and their […]
We are delighted to announce the new Board of Lung Cancer Europe (LuCE) elected at our AGM in Zagreb last […]
Lung Cancer Europe (LuCE) Annual General Meeting and General Assembly The Lung Cancer Europe (LuCE) AGM and General Assembly take […]
Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]
Financial impact of lung cancer: A European perspective High risk of financial vulnerability after diagnosis: The majority of people impacted […]
This is an annual initiative led by lung cancer patient organisations, across Europe with the purpose of raising awareness relating […]
Join us at our launch of the 8th LuCE report: “Financial impact on lung cancer: A European Perspective”
November 14th – 15th in Amsterdam We are delighted to announce that Lung Cancer Europe (LuCE) is participating in a two-day meeting […]
We are very sad to share the heartbreaking news that Marjo Forsblom passed away on Sunday October 22nd 2023. Marjo […]
consectetur adipisicing elit, sed do eiusmod tempor incididunt laboret dolore magna aliqua. Ut enim minim veniam quis nostrud exercitation ullamco laboris.
